10-Q: Quarterly report [Sections 13 or 15(d)]
Published on May 10, 2007
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D. C. 20549
Form
10-Q
x
QUARTERLY REPORT
PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF
1934
For
quarterly period ended March 31, 2007
o
TRANSITION REPORT
PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF
1934
For
the
transition period from ____________ to _____________
Commission
File Number: 0-11576
HARRIS
& HARRIS GROUP, INC.
(Exact
name of registrant as specified in its charter)
New
York
|
13-3119827
|
(State
or other jurisdiction of
|
(IRS
Employer Identification No.)
|
incorporation
or organization)
|
|
|
|
111
West 57th
Street, New York, New York
|
10019
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(212)
582-0900
(Registrant's
telephone number, including area code)
Indicate
by check mark whether the registrant (1) has filed all reports required to
be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements
for
the past 90 days.
Yes x No
o
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer or a non-accelerated filer (as defined in Rule 12b-2 of the
Exchange Act).
Large
Accelerated Filer o Accelerated
Filer x Non-Accelerated
Filer o
Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act).
Yes
o No x
Indicate
the number of shares outstanding of each of the issuer's classes of common
stock, as of the latest practicable date.
Class
|
Outstanding
at May 10, 2007
|
Common
Stock, $0.01 par value per share
|
21,341,029
shares
|
Harris
& Harris Group, Inc.
Form
10-Q, March 31, 2007
Page
Number
|
||||
PART
I. FINANCIAL INFORMATION
|
||||
Item
1. Consolidated Financial Statements
|
1
|
|||
Consolidated
Statements of Assets and Liabilities
|
2
|
|||
Consolidated
Statements of Operations
|
3
|
|||
Consolidated
Statements of Cash Flows
|
4
|
|||
Consolidated
Statements of Changes in Net Assets
|
5
|
|||
Consolidated
Schedule of Investments
|
6
|
|||
Notes
to Consolidated Financial Statements
|
18
|
|||
Financial
Highlights
|
25
|
|||
Item
2. Management's Discussion and Analysis of Financial Condition and
Results
of Operations
|
26
|
|||
Background
and Overview
|
26
|
|||
Results
of Operations
|
30
|
|||
Financial
Condition
|
31
|
|||
Liquidity
|
33
|
|||
Capital
Resources
|
33
|
|||
Critical
Accounting Policies
|
33
|
|||
Recent
Developments - Portfolio Companies
|
35
|
|||
Forward
Looking Statements
|
35
|
|||
Item
3. Quantitative and Qualitative Disclosures About Market
Risk
|
36
|
|||
Item
4. Controls and Procedures
|
37
|
|||
PART
II. OTHER INFORMATION
|
||||
Item
1A. Risk Factors
|
38
|
|||
Item
6. Exhibits
|
38
|
|||
Signatures
|
39
|
|||
Exhibit
Index
|
40
|
PART
I. FINANCIAL INFORMATION
Item
1. Consolidated Financial Statements
The
information furnished in the accompanying consolidated financial statements
reflects all adjustments that are, in the opinion of management, necessary
for a
fair statement of the results for the interim period presented.
Harris
& Harris Group, Inc.®
(the
"Company," "us," "our" and "we"), is an internally managed venture capital
company that has operated as a business development company under the Investment
Company Act of 1940 (the "1940 Act"). Certain information and disclosures
normally included in the consolidated financial statements in accordance with
Generally Accepted Accounting Principles have been condensed or omitted as
permitted by Regulation S-X and Regulation S-K. The accompanying consolidated
financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto for the year ended December 31, 2006,
contained in our Annual Report on Form 10-K for the year ended December 31,
2006.
On
September 25, 1997, our Board of Directors approved a proposal to seek
qualification as a regulated investment company ("RIC") under Subchapter M
of
the Internal Revenue Code (the "Code"). At that time, we were taxable under
Subchapter C of the Code (a "C Corporation"). In order to qualify as a RIC,
we
must, in general (1) annually, derive at least 90 percent of our gross income
from dividends, interest, gains from the sale of securities and similar sources;
(2) quarterly, meet certain investment diversification requirements; and (3)
annually, distribute at least 90 percent of our investment company taxable
income as a dividend. In addition to the requirement that we must annually
distribute at least 90 percent of our investment company taxable income, we
may
either distribute or retain our taxable net capital gains from investments,
but
any net capital gains not distributed could be subject to corporate level tax.
Further, we could be subject to a four percent excise tax to the extent we
fail
to distribute at least 98 percent of our annual investment company taxable
income and would be subject to income tax to the extent we fail to distribute
100 percent of our investment company taxable income.
Because
of the specialized nature of our investment portfolio, we generally can satisfy
the diversification requirements under Subchapter M of the Code if we receive
a
certification from the Securities and Exchange Commission (“SEC”) that we are
"principally engaged in the furnishing of capital to other corporations which
are principally engaged in the development or exploitation of inventions,
technological improvements, new processes, or products not previously generally
available."
On
June
16, 2006, we received SEC certification for 2005, permitting us to qualify
for
RIC treatment for 2005 (as we had for the years 1999 through 2004) pursuant
to
Section 851(e) of the Code. Although the SEC certification for 2005 was issued,
there can be no assurance that we will qualify for or receive such certification
for subsequent years (to the extent we need additional certification as a result
of changes in our portfolio) or that we will actually qualify for Subchapter
M
treatment in subsequent years. In addition, under certain circumstances, even
if
we qualified for Subchapter M treatment in a given year, we might take action
in
a subsequent year to ensure that we would be taxed in that subsequent year
as a
C Corporation, rather than as a RIC. On March 29, 2007, we filed for RIC
certification under Section 851(e) of the Code for 2006, although we qualified
as a RIC in 2006 without such certification.
1
HARRIS
& HARRIS GROUP, INC.
CONSOLIDATED
STATEMENTS OF ASSETS AND LIABILITIES
March
31, 2007
|
December
31, 2006
|
||||||
(Unaudited)
|
|||||||
ASSETS
|
|||||||
Investments,
at value (Cost: $125,055,760 at 3/31/07,
|
|||||||
$121,331,398
at 12/31/06)
|
$ |
112,410,877
|
$ |
112,323,978
|
|||
Cash
and cash equivalents
|
550,452
|
2,071,788
|
|||||
Restricted
funds
|
2,258,665
|
2,149,785
|
|||||
Receivable
from broker
|
0
|
819,905
|
|||||
Interest
receivable
|
563,375
|
625,372
|
|||||
Prepaid
expenses
|
427,580
|
10,945
|
|||||
Other
assets
|
297,754
|
326,817
|
|||||
Total
assets
|
$ |
116,508,703
|
$ |
118,328,590
|
|||
LIABILITIES
& NET ASSETS
|
|||||||
Accounts
payable and accrued liabilities
|
$ |
3,906,008
|
$ |
4,115,300
|
|||
Accrued
profit sharing (Note 5)
|
0
|
261,661
|
|||||
Deferred
rent
|
19,626
|
21,326
|
|||||
Current
taxes payable
|
56,767
|
0
|
|||||
Total
liabilities
|
3,982,401
|
4,398,287
|
|||||
Net
assets
|
$ |
112,526,302
|
$ |
113,930,303
|
|||
Net
assets are comprised of:
|
|||||||
Preferred
stock, $0.10 par value,
|
|||||||
2,000,000
shares authorized; none issued
|
$ |
0
|
$ |
0
|
|||
Common
stock, $0.01 par value, 45,000,000 shares authorized at
|
|||||||
3/31/07
and 12/31/06; 23,169,769 issued at 3/31/07 and
|
|||||||
22,843,757
issued at 12/31/06
|
231,698
|
228,438
|
|||||
Additional
paid-in capital (Note 8)
|
134,784,100
|
129,801,201
|
|||||
Accumulated
net realized loss
|
(6,500,609
|
)
|
(3,747,912
|
)
|
|||
Accumulated
unrealized depreciation of investments
|
(12,644,883
|
)
|
(9,007,420
|
)
|
|||
Unrecognized
net gain on retirement benefit plans
|
61,527
|
61,527
|
|||||
Treasury
stock, at cost (1,828,740 shares at 3/31/07 and
|
|||||||
1,828,740
shares at 12/31/06)
|
(3,405,531
|
)
|
(3,405,531
|
)
|
|||
Net
assets
|
$ |
112,526,302
|
$ |
113,930,303
|
|||
Shares
outstanding
|
21,341,029
|
21,015,017
|
|||||
Net
asset value per outstanding share
|
$ |
5.27
|
$ |
5.42
|
The
accompanying notes are an integral part of these consolidated financial
statements.
2
HARRIS
&
HARRIS
GROUP,
INC.
CONSOLIDATED
STATEMENTS OF OPERATIONS
(Unaudited)
Three
Months Ended
|
|
Three
Months Ended
|
|
||||
|
|
March
31, 2007
|
|
March
31, 2006
|
|||
Investment
income:
|
|||||||
Interest
from:
|
|||||||
Fixed
income securities
|
$
|
652,498
|
$
|
802,362
|
|||
Miscellaneous
income
|
0
|
2,500
|
|||||
Total
investment income
|
652,498
|
804,862
|
|||||
Expenses:
|
|||||||
Salaries,
benefits and stock-based
|
|||||||
Compensation
(Note 4)
|
2,534,766
|
786,361
|
|||||
Administration
and operations
|
380,865
|
322,449
|
|||||
Professional
fees
|
182,195
|
289,887
|
|||||
Rent
|
59,507
|
61,238
|
|||||
Directors'
fees and expenses
|
141,196
|
85,902
|
|||||
Depreciation
|
15,313
|
16,768
|
|||||
Custodian
fees
|
5,774
|
10,000
|
|||||
Total
expenses
|
3,319,616
|
1,572,605
|
|||||
Net
operating loss
|
(2,667,118
|
)
|
(767,743
|
)
|
|||
Net
realized gain (loss) from investments:
|
|||||||
Realized
(loss) gain from investments
|
(674
|
)
|
11,953
|
||||
Income
tax expense (Note 7)
|
84,905
|
9,606
|
|||||
Net
realized (loss) gain from investments
|
(85,579
|
)
|
2,347
|
||||
Net
realized loss
|
(2,752,697
|
)
|
(765,396
|
)
|
|||
Net
increase in unrealized depreciation
|
|||||||
on
investments:
|
|||||||
Change
as a result of investment sales
|
0
|
0
|
|||||
Change
on investments held
|
(3,637,463
|
)
|
(888,594
|
)
|
|||
Change
in unrealized depreciation on investments
|
(3,637,463
|
)
|
(888,594
|
)
|
|||
Net
increase in unrealized depreciation
|
|||||||
on
investments
|
(3,637,463
|
)
|
(888,594
|
)
|
|||
Net
decrease in net assets resulting
|
|||||||
from
operations:
|
|||||||
Total
|
$
|
(6,390,160
|
)
|
$
|
(1,653,990
|
)
|
|
Per
average basic and diluted outstanding share
|
$
|
(0.30
|
)
|
$
|
(0.08
|
)
|
|
Average
outstanding shares
|
21,277,576
|
20,756,345
|
The
accompanying notes are an integral part of these consolidated financial
statements.
3
HARRIS
& HARRIS GROUP, INC.
CONSOLIDATED
STATEMENTS OF CASH FLOWS
(Unaudited)
Three
Months Ended
|
|
Three
Months Ended
|
|
||||
|
|
March
31, 2007
|
|
March
31, 2006
|
|||
Cash
flows used in operating activities:
|
|||||||
Net
decrease in net assets resulting from operations
|
$
|
(6,390,160
|
)
|
$
|
(1,653,990
|
)
|
|
Adjustments
to reconcile net decrease in net assets
|
|||||||
resulting
from operations to net cash used in
|
|||||||
operating
activities:
|
|||||||
Net
realized and unrealized loss on investments
|
3,638,137
|
876,641
|
|||||
Depreciation
and amortization
|
(65,730
|
)
|
(295,811
|
)
|
|||
Stock-based
compensation expense
|
1,690,181
|
0
|
|||||
Changes
in assets and liabilities:
|
|||||||
Restricted
funds
|
(108,880
|
)
|
(170,644
|
)
|
|||
Receivable
from portfolio company
|
0
|
75,000
|
|||||
Interest
receivable
|
61,997
|
(316,696
|
)
|
||||
Receivable
from broker
|
819,905
|
0
|
|||||
Prepaid
expenses
|
(416,635
|
)
|
(449,037
|
)
|
|||
Other
assets
|
(10,191
|
)
|
0
|
||||
Accounts
payable and accrued liabilities
|
(209,292
|
)
|
236,796
|
||||
Accrued
profit sharing
|
(261,661
|
)
|
(1,897,072
|
)
|
|||
Deferred
rent
|
(1,700
|
)
|
(1,701
|
)
|
|||
Current
income tax liability
|
80,795
|
(8,282,830
|
)
|
||||
Net
cash used
in operating activities
|
(1,173,234
|
)
|
(11,879,344
|
)
|
|||
Cash
flows from investing activities:
|
|||||||
Purchase
of short-term investments
|
|||||||
and
marketable securities
|
(10,952,109
|
)
|
(67,883,929
|
)
|
|||
Sale
of short-term investments and marketable securities
|
12,165,656
|
92,418,871
|
|||||
Investment
in private placements and loans
|
(4,857,357
|
)
|
(9,412,764
|
)
|
|||
Proceeds
from sale of investments
|
0
|
20,688
|
|||||
Purchase
of fixed assets
|
(270
|
)
|
(5,989
|
)
|
|||
Net
cash (used in) provided by investing activities
|
(3,644,080
|
)
|
15,136,877
|
||||
Cash
flows from financing activities:
|
|||||||
Proceeds
from stock option exercises (Note 4)
|
3,295,978
|
0
|
|||||
Net
cash provided by financing activities
|
3,295,978
|
0
|
|||||
Net
(decrease) increase in cash and cash equivalents:
|
|||||||
Cash
and cash equivalents at beginning of the period
|
2,071,788
|
1,213,289
|
|||||
Cash
and cash equivalents at end of the period
|
550,452
|
4,470,822
|
|||||
Net
(decrease) increase in cash and cash equivalents
|
$
|
(1,521,336
|
)
|
$
|
3,257,533
|
||
Supplemental
disclosures of cash flow information:
|
|||||||
Income
taxes paid
|
$
|
10,252
|
$
|
8,291,973
|
The
accompanying notes are an integral part of these consolidated financial
statements.
4
HARRIS
& HARRIS GROUP, INC.
CONSOLIDATED
STATEMENTS OF CHANGES IN NET ASSETS
Three
Months Ended
|
|
Year
Ended
|
|
||||
|
|
March
31, 2007
|
|
December
31, 2006
|
|
||
|
|
(Unaudited)
|
|
|
|||
Changes
in net assets from operations:
|
|||||||
Net
operating loss
|
$
|
(2,667,118
|
)
|
$
|
(7,612,935
|
)
|
|
Net
realized (loss) gain on investments
|
(85,579
|
)
|
258,693
|
||||
Net
increase in unrealized depreciation
|
|||||||
on
investments held
|
(3,637,463
|
)
|
(4,418,870
|
)
|
|||
Net
decrease in net assets resulting
|
|||||||
from
operations
|
(6,390,160
|
)
|
(11,773,112
|
)
|
|||
Changes
in net assets from capital
|
|||||||
stock
transactions:
|
|||||||
Issuance
of common stock upon the
|
|||||||
exercise
of stock options
|
3,260
|
2,587
|
|||||
Additional
paid-in capital on common
|
|||||||
stock
issued
|
3,292,718
|
2,612,603
|
|||||
Stock-based
compensation expense
|
1,690,181
|
5,038,956
|
|||||
Net
increase in net assets resulting from
|
|||||||
capital
stock transactions
|
4,986,159
|
7,654,146
|
|||||
Changes
in net assets from adoption
|
|||||||
of
SFAS No. 158
|
0
|
61,527
|
|||||
Net
decrease in net assets
|
(1,404,001
|
)
|
(4,057,439
|
)
|
|||
Net
assets:
|
|||||||
Beginning
of the period
|
113,930,303
|
117,987,742
|
|||||
End
of the period
|
$
|
112,526,302
|
$
|
113,930,303
|
The
accompanying notes are an integral part of these consolidated financial
statements.
5
HARRIS
& HARRIS GROUP, INC.
CONSOLIDATED
SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2007
(Unaudited)
Method
of
|
|
Shares/
|
|
|
|
|||||
|
|
Valuation
(3)
|
|
Principal
|
|
Value
|
||||
Investments
in Unaffiliated Companies (6)(7) - 15.97% of net
assets
|
||||||||||
Private
Placement Portfolio (Illiquid) - 15.97% of net
assets
|
||||||||||
AlphaSimplex
Group, LLC (2) — Investment
management company
|
||||||||||
headed
by Dr. Andrew W. Lo, holder of the Harris & Harris
Group
|
||||||||||
Chair
at MIT
|
||||||||||
Limited
Liability Company Interest
|
(B
|
)
|
—
|
$
|
11,036
|
|||||
Exponential
Business Development Company (1)(2) —
|
||||||||||
Venture
capital partnership focused on early stage companies
|
||||||||||
Limited
Partnership Interest
|
(B
|
)
|
—
|
0
|
||||||
Molecular
Imprints, Inc. (1)(2) — Manufacturing nanoimprint
|
||||||||||
lithography
capital equipment
|
||||||||||
Series
B Convertible Preferred Stock
|
(A
|
)
|
1,333,333
|
2,000,000
|
||||||
Series
C Convertible Preferred Stock
|
(A
|
)
|
1,250,000
|
2,500,000
|
||||||
Warrants
at $2.00 expiring 12/31/11
|
(B
|
)
|
125,000
|
0
|
||||||
4,500,000
|
||||||||||
Nanosys,
Inc. (1)(2)(5) — Developing zero and one-dimensional
|
||||||||||
inorganic
nanometer-scale materials and devices
|
||||||||||
Series
C Convertible Preferred Stock
|
(C
|
)
|
803,428
|
2,370,113
|
||||||
Series
D Convertible Preferred Stock
|
(C
|
)
|
1,016,950
|
3,000,003
|
||||||
5,370,116
|
||||||||||
Nantero,
Inc. (1)(2)(5) — Developing a high-density, nonvolatile,
|
||||||||||
random
access memory chip, enabled by carbon nanotubes
|
||||||||||
Series
A Convertible Preferred Stock
|
(C
|
)
|
345,070
|
1,046,908
|
||||||
Series
B Convertible Preferred Stock
|
(C
|
)
|
207,051
|
628,172
|
||||||
Series
C Convertible Preferred Stock
|
(C
|
)
|
188,315
|
571,329
|
||||||
2,246,409
|
The
accompanying notes are an integral part of these consolidated financial
statements.
6
HARRIS
& HARRIS GROUP, INC.
CONSOLIDATED
SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2007
(Unaudited)
|
|
Method
of
|
Shares/
|
|||||||
Valuation
(3)
|
Principal
|
Value
|
||||||||
Investments
in Unaffiliated Companies (6)(7) - 15.97% of net assets
(cont.)
|
||||||||||
Private
Placement Portfolio (Illiquid) - 15.97% of net assets
(cont.)
|
||||||||||
NeoPhotonics
Corporation (1)(2) — Developing and manufacturing
|
||||||||||
optical
devices and components
|
||||||||||
Common
Stock
|
(C
|
)
|
716,195
|
$
|
133,141
|
|||||
Series
1 Convertible Preferred Stock
|
(C
|
)
|
1,831,256
|
1,831,256
|
||||||
Series
2 Convertible Preferred Stock
|
(C
|
)
|
741,898
|
741,898
|
||||||
Series
3 Convertible Preferred Stock
|
(C
|
)
|
2,750,000
|
2,750,000
|
||||||
Warrants
at $0.15 expiring 01/26/10
|
(C
|
)
|
16,364
|
164
|
||||||
Warrants
at $0.15 expiring 12/05/10
|
(C
|
)
|
14,063
|
140
|
||||||
5,456,599
|
||||||||||
Polatis,
Inc. (1)(2)(5)(10) — Developing MEMS-based optical
|
||||||||||
networking
components
|
||||||||||
Series
A-1 Convertible Preferred Stock
|
(B
|
)
|
16,775
|
0
|
||||||
Series
A-2 Convertible Preferred Stock
|
(B
|
)
|
71,611
|
320,282
|
||||||
Series
A-4 Convertible Preferred Stock
|
(B
|
)
|
4,774
|
21,353
|
||||||
Series
A-5 Convertible Preferred Stock
|
(B
|
)
|
5,491
|
45,127
|
||||||
386,762
|
||||||||||
Total
Unaffiliated Private Placement Portfolio (cost:
$18,106,450)
|
$
|
17,970,922
|
||||||||
Total
Investments in Unaffiliated Companies (cost:
$18,106,450)
|
$
|
17,970,922
|
The
accompanying notes are an integral part of these consolidated financial
statements.
7
HARRIS
& HARRIS GROUP, INC.
CONSOLIDATED
SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2007
(Unaudited)
Method
of
|
|
Shares/
|
|
|
|
|||||
|
|
Valuation
(3)
|
|
Principal
|
|
Value
|
||||
Investments
in Non-Controlled Affiliated Companies (6)(8) - 30.39% of net
assets
|
||||||||||
Private
Placement Portfolio (Illiquid)
- 30.39% of net assets
|
||||||||||
Adesto
Technologies Corporation (1)(2)(4)(5) — Developing
|
||||||||||
semiconductor-related
products enabled at the nanoscale
|
||||||||||
Series
A Convertible Preferred Stock
|
(A
|
)
|
3,416,149
|
$
|
1,147,826
|
|||||
BridgeLux,
Inc. (1)(2)(11) — Manufacturing high-power light
|
||||||||||
emitting
diodes
|
||||||||||
Series
B Convertible Preferred Stock
|
(A
|
)
|
1,861,504
|
1,000,000
|
||||||
Secured
Convertible Bridge Note (including interest)
|
(A
|
)
|
$
|
350,877
|
355,398
|
|||||
1,355,398
|
||||||||||
Cambrios
Technologies Corporation (1)(2)(5) — Developing
|
||||||||||
nanowire-enabled
electronic materials for the display industry
|
||||||||||
Series
B Convertible Preferred Stock
|
(C
|
)
|
1,294,025
|
1,294,025
|
||||||
Series
C Convertible Preferred Stock
|
(C
|
)
|
1,300,000
|
1,300,000
|
||||||
2,594,025
|
||||||||||
Chlorogen,
Inc. (1)(2)(5) — Developing patented chloroplast
|
||||||||||
technology
to produce plant-made proteins
|
||||||||||
Series
A Convertible Preferred Stock
|
(B
|
)
|
4,478,038
|
0
|
||||||
Series
B Convertible Preferred Stock
|
(B
|
)
|
2,077,930
|
0
|
||||||
Secured
Convertible Bridge Note (including interest)
|
(B
|
)
|
$
|
221,438
|
0
|
|||||
0
|
||||||||||
Crystal
IS, Inc. (1)(2)(5) — Developing single-crystal
|
||||||||||
aluminum
nitride substrates for optoelectronic devices
|
||||||||||
Series
A Convertible Preferred Stock
|
(C
|
)
|
391,571
|
305,425
|
||||||
Series
A-1 Convertible Preferred Stock
|
(C
|
)
|
1,300,376
|
1,014,294
|
||||||
Warrants
at $0.78 expiring 05/05/2013
|
(B
|
)
|
15,231
|
0
|
||||||
Warrants
at $0.78 expiring 05/12/2013
|
(B
|
)
|
2,350
|
0
|
||||||
Warrants
at $0.78 expiring 08/08/2013
|
(B
|
)
|
4,396
|
0
|
||||||
1,319,719
|
||||||||||
CSwitch,
Inc. (1)(2)(5) — Developing next-generation, system-on-
|
||||||||||
a-chip
solutions for communications-based platforms
|
||||||||||
Series
A-1 Convertible Preferred Stock
|
(C
|
)
|
6,700,000
|
3,350,000
|
The
accompanying notes are an integral part of these consolidated financial
statements.
8
HARRIS
&
HARRIS
GROUP, INC.
CONSOLIDATED
SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2007
(Unaudited)
Method
of
|
|
Shares/
|
|
|
|
|||||
|
|
Valuation
(3)
|
|
Principal
|
|
Value
|
||||
Investments
in Non-Controlled Affiliated Companies (6)(8) - 30.39% of net assets
(cont.)
|
||||||||||
Private
Placement Portfolio (Illiquid)
- 30.39% of net assets (cont.)
|
||||||||||
D-Wave
Systems, Inc. (1)(2)(5)(13) — Developing high-
|
||||||||||
performance
quantum computing systems
|
||||||||||
Series
B Convertible Preferred Stock
|
(A
|
)
|
2,000,000
|
$
|
1,734,600
|
|||||
Warrants
at $0.85 expiring 10/19/07
|
(B
|
)
|
1,800,000
|
0
|
||||||
1,734,600
|
||||||||||
Innovalight,
Inc. (1)(2)(5) - Developing renewable energy
|
||||||||||
products
enabled by silicon-based nanomaterials
|
||||||||||
Series
B Convertible Preferred Stock
|
(A
|
)
|
16,666,666
|
2,500,000
|
||||||
Kereos,
Inc. (1)(2)(5) — Developing emulsion-based imaging
|
||||||||||
agents
and targeted therapeutics to image and treat cancer
|
||||||||||
and
cardiovascular disease
|
||||||||||
Series
B Convertible Preferred Stock
|
(A
|
)
|
545,456
|
1,500,000
|
||||||
Kovio,
Inc. (1)(2)(5) — Developing semiconductor products
|
||||||||||
using
printed electronics and thin-film technologies
|
||||||||||
Series
C Convertible Preferred Stock
|
(A
|
)
|
2,500,000
|
3,000,000
|
||||||
Mersana
Therapeutics, Inc. (1)(2)(5)(12) — Developing advanced
|
||||||||||
polymers
for drug delivery
|
||||||||||
Series
A Convertible Preferred Stock
|
(C
|
)
|
68,452
|
136,904
|
||||||
Series
B Convertible Preferred Stock
|
(C
|
)
|
616,500
|
1,233,000
|
||||||
Warrants
at $2.00 expiring 10/21/10
|
(B
|
)
|
91,625
|
0
|
||||||
1,369,904
|
||||||||||
Metabolon,
Inc. (1)(2)(5) - Discovering biomarkers through
|
||||||||||
the
use of metabolomics
|
||||||||||
Series
B Convertible Preferred Stock
|
(A
|
)
|
2,173,913
|
2,500,000
|
The
accompanying notes are an integral part of these consolidated financial
statements.
9
HARRIS
& HARRIS GROUP, INC.
CONSOLIDATED
SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2007
(Unaudited)
Method
of
|
|
Shares/
|
|
|
|
|||||
|
|
Valuation
(3)
|
|
Principal
|
|
Value
|
||||
Investments
in Non-Controlled Affiliated Companies (6)(8) - 30.39% of net assets
(cont.)
|
||||||||||
Private
Placement Portfolio (Illiquid)
- 30.39% of net assets (cont.)
|
||||||||||
NanoGram
Corporation (1)(2)(5) — Developing a broad suite of
intellectual property
utilizing nanoscale materials
|
||||||||||
Series
I Convertible Preferred Stock
|
(C
|
)
|
63,210
|
$
|
64,259
|
|||||
Series
II Convertible Preferred Stock
|
(C
|
)
|
1,250,904
|
1,271,670
|
||||||
Series
III Convertible Preferred Stock
|
(C
|
)
|
1,242,144
|
1,262,764
|
||||||
2,598,693
|
||||||||||
Nanomix,
Inc. (1)(2)(5) — Producing nanoelectronic sensors that
|
||||||||||
integrate
carbon nanotube electronics with silicon microstructures
|
||||||||||
Series
C Convertible Preferred Stock
|
(B
|
)
|
9,779,181
|
330,228
|
||||||
NanoOpto
Corporation (1)(2)(5) — Manufacturing discrete and integrated optical
communications sub-components on a chip by utilizing nano manufacturing
and nano coating technology
|
||||||||||
Series
A-1 Convertible Preferred Stock
|
(B
|
)
|
267,857
|
0
|
||||||
Series
B Convertible Preferred Stock
|
(B
|
)
|
3,819,935
|
0
|
||||||
Series
C Convertible Preferred Stock
|
(B
|
)
|
1,932,789
|
0
|
||||||
Series
D Convertible Preferred Stock
|
(B
|
)
|
1,397,218
|
49,121
|
||||||
Secured
Convertible Bridge Note (including interest)
|
(B
|
)
|
268,654
|
537,308
|
||||||
Warrants
at $0.4359 expiring 03/15/10
|
(B
|
)
|
193,279
|
0
|
||||||
586,429
|
||||||||||
Nextreme
Thermal Solutions, Inc. (1)(2)(5) — Developing thin-film
|
||||||||||
thermoelectric
devices for cooling and energy conversion
|
||||||||||
Series
A Convertible Preferred Stock
|
(C
|
)
|
1,750,000
|
1,750,000
|
||||||
Questech
Corporation (1)(2) — Manufacturing and marketing
|
||||||||||
proprietary
metal and stone decorative tiles
|
||||||||||
Common
Stock
|
(B
|
)
|
655,454
|
905,050
|
||||||
Warrants
at $1.50 expiring 11/21/07
|
(B
|
)
|
3,750
|
0
|
||||||
Warrants
at $1.50 expiring 11/19/08
|
(B
|
)
|
5,000
|
0
|
||||||
Warrants
at $1.50 expiring 11/19/09
|
(B
|
)
|
5,000
|
0
|
||||||
905,050
|
The
accompanying notes are an integral part of these consolidated financial
statements.
10
HARRIS
& HARRIS GROUP, INC.
CONSOLIDATED
SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2007
(Unaudited)
Method
of
|
|
Shares/
|
|
|
|
|||||
|
|
Valuation
(3)
|
|
Principal
|
|
Value
|
||||
Investments
in Non-Controlled Affiliated Companies (6)(8) - 30.39% of net assets
(cont.)
|
||||||||||
Private
Placement Portfolio (Illiquid)
- 30.39% of net assets (cont.)
|
||||||||||
Solazyme,
Inc. (1)(2)(5) — Developing energy-harvesting
|
||||||||||
machinery
of photosynthetic microbes to produce industrial
|
||||||||||
and
pharmaceutical molecules
|
||||||||||
Series
A Convertible Preferred Stock
|
(C
|
)
|
988,204
|
$
|
385,400
|
|||||
Series
B Convertible Preferred Stock
|
(C
|
)
|
495,246
|
500,000
|
||||||
885,400
|
||||||||||
Starfire
Systems, Inc. (1)(2)(5) — Producing ceramic-forming polymers
|
||||||||||
Common
Stock
|
(A
|
)
|
375,000
|
150,000
|
||||||
Series
A-1 Convertible Preferred Stock
|
(C
|
)
|
600,000
|
600,000
|
||||||
750,000
|
||||||||||
Xradia,
Inc. (1)(2) - Designing, manufacturing and selling ultra
high
|
||||||||||
resolution
3D x-ray microscopes and fluorescence imaging systems.
|
||||||||||
Series
D Convertible Preferred Stock
|
(A
|
)
|
3,121,099
|
4,000,000
|
||||||
Zia
Laser, Inc. (1)(2)(5) — Developing quantum dot semiconductor
lasers
|
||||||||||
Series
C Convertible Preferred Stock
|
(B
|
)
|
1,500,000
|
15,000
|
||||||
Total
Non-Controlled Private Placement Portfolio (cost:
$44,432,534)
|
$
|
34,192,272
|
||||||||
Total
Investments in Non-Controlled Affiliated Companies (cost:
$44,432,534)
|
$
|
34,192,272
|
The
accompanying notes are an integral part of these consolidated financial
statements.
11
HARRIS
& HARRIS GROUP, INC.
CONSOLIDATED
SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2007
(Unaudited)
Method
of
|
|
Shares/
|
|
|
|
|||||
|
|
Valuation
(3)
|
|
Principal
|
|
Value
|
||||
Investments
in Controlled Affiliated Companies (6)(9) - 2.25% of net
assets
|
||||||||||
Private
Placement Portfolio (Illiquid)
- 2.25% of net assets
|
||||||||||
Evolved
Nanomaterial Sciences, Inc. (1)(2)(5) -- Developing
|
||||||||||
nanoscale-enhanced
approaches for the resolution of
|
||||||||||
chiral
molecules
|
||||||||||
Series
A Convertible Preferred Stock
|
(B
|
)
|
5,870,021
|
$
|
1,571,719
|
|||||
SiOnyx,
Inc. (1)(2)(5) -- Developing silicon-based
|
||||||||||
optoelectronic
products enabled by its proprietary "Black Silicon"
|
||||||||||
Series
A Convertible Preferred Stock
|
(C
|
)
|
233,499
|
70,050
|
||||||
Series
A-1 Convertible Preferred Stock
|
(C
|
)
|
2,966,667
|
890,000
|
||||||
960,050
|
||||||||||
Total
Controlled Private Placement Portfolio (cost:
$4,440,000)
|
$
|
2,531,769
|
||||||||
Total
Investments in Controlled Affiliated Companies (cost:
$4,440,000)
|
$
|
2,531,769
|
||||||||
U.S.
Government and Agency Securities - 51.29% of net
assets
|
||||||||||
U.S.
Treasury Bill -- due date 4/12/07
|
(J
|
)
|
1,000,000
|
998,620
|
||||||
U.S.
Treasury Notes -- due date 11/30/07, coupon 4.25%
|
(H
|
)
|
6,500,000
|
6,468,540
|
||||||
U.S.
Treasury Notes -- due date 02/15/08, coupon 3.375%
|
(H
|
)
|
9,000,000
|
8,880,120
|
||||||
U.S.
Treasury Notes -- due date 05/15/08, coupon 3.75%
|
(H
|
)
|
9,000,000
|
8,892,810
|
||||||
U.S.
Treasury Notes -- due date 09/15/08, coupon 3.125%
|
(H
|
)
|
5,000,000
|
4,886,500
|
||||||
U.S.
Treasury Notes -- due date 01/15/09, coupon 3.25%
|
(H
|
)
|
3,000,000
|
2,927,940
|
||||||
U.S.
Treasury Notes -- due date 02/15/09, coupon 4.50%
|
(H
|
)
|
5,100,000
|
5,086,434
|
||||||
U.S.
Treasury Notes -- due date 04/15/09, coupon 3.125%
|
(H
|
)
|
3,000,000
|
2,914,350
|
||||||
U.S.
Treasury Notes -- due date 07/15/09, coupon 3.625%
|
(H
|
)
|
3,000,000
|
2,938,470
|
||||||
U.S.
Treasury Notes -- due date 10/15/09, coupon 3.375%
|
(H
|
)
|
3,000,000
|
2,915,400
|
||||||
U.S.
Treasury Notes -- due date 01/15/10, coupon 3.625%
|
(H
|
)
|
3,000,000
|
2,927,940
|
||||||
U.S.
Treasury Notes -- due date 04/15/10, coupon 4.00%
|
(H
|
)
|
3,000,000
|
2,954,070
|
||||||
U.S.
Treasury Notes -- due date 07/15/10, coupon 3.875%
|
(H
|
)
|
3,000,000
|
2,942,460
|
||||||
U.S.
Treasury Notes -- due date 10/15/10, coupon 4.25%
|
(H
|
)
|
2,000,000
|
1,982,260
|
||||||
Total
Investments in U.S. Government and Agency Securities (cost:
$58,076,776)
|
$
|
57,715,914
|
||||||||
Total
Investments (cost: $125,055,760)
|
$
|
112,410,877
|
The
accompanying notes are an integral part of these consolidated financial
statements.
12
HARRIS
& HARRIS GROUP, INC.
CONSOLIDATED
SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2007
(Unaudited)
Notes
to
Consolidated Schedule of Investments
(1)
|
Represents
a non-income producing security. Equity investments that have not
paid
dividends within the last 12 months are considered to be non-income
producing.
|
(2)
|
Legal
restrictions on sale of investment.
|
(3)
|
See
Footnote to Schedule of Investments for a description of the Valuation
Procedures.
|
(4)
|
Initial
investment was made during 2007.
|
(5)
|
These
investments are development stage companies. A development stage
company
is defined as a company that is devoting substantially all of its
efforts
to establishing a new business, and either it has not yet commenced
its
planned principal operations, or it has commenced such operations
but has
not realized significant revenue from
them.
|
(6)
|
Investments
in unaffiliated companies consist of investments in which we own
less than
five percent of the voting shares of the portfolio company. Investments
in
non-controlled affiliated companies consist of investments in which
we own
five percent or more, but less than 25 percent, of the voting shares
of
the portfolio company or where we hold one or more seats on the portfolio
company’s Board of Directors. Investments in controlled affiliated
companies consist of investments in which we own 25 percent or more
of the
voting shares of the portfolio
company.
|
(7)
|
The
aggregate cost for federal income tax purposes of investments in
unaffiliated companies is $18,106,450. The gross unrealized appreciation
based on the tax cost for these securities is $1,732,194. The gross
unrealized depreciation based on the tax cost for these securities
is
$1,867,722.
|
(8)
|
The
aggregate cost for federal income tax purposes of investments in
non-controlled affiliated companies is $44,432,534. The gross unrealized
appreciation based on the tax cost for these securities is $333,269.
The
gross unrealized depreciation based on the tax cost for these securities
is $10,573,531.
|
(9)
|
The
aggregate cost for federal income tax purposes of investments in
controlled affiliated companies is $4,440,000. The gross unrealized
appreciation based on the tax cost for these securities is $0. The
gross
unrealized depreciation based on the tax cost for these securities
is
$1,908,231.
|
(10)
|
Continuum
Photonics, Inc., merged with Polatis, Ltd., to form Polatis,
Inc.
|
(11)
|
BridgeLux,
Inc., was previously named eLite Optoelectronics,
Inc.
|
(12)
|
Mersana
Therapeutics, Inc., was previously named Nanopharma
Corp.
|
(13)
|
D-Wave
Systems, Inc., is located and is doing business primarily in Canada.
We
invested in D-Wave Systems, Inc., through D-Wave USA, a Delaware
company.
Our investment is denominated in Canadian dollars and is subject
to
foreign currency translation. Refer to Note 3 "Significant Accounting
Policies."
|
The
accompanying notes are an integral part of this consolidated
schedule.
13
HARRIS
& HARRIS GROUP, INC.
FOOTNOTE
TO CONSOLIDATED SCHEDULE OF INVESTMENTS
(Unaudited)
VALUATION
PROCEDURES
Our
investments can be classified into five broad categories for valuation
purposes:
Equity-Related
Securities;
Investments
in Intellectual Property or Patents or Research and Development in Technology
or
Product Development;
Long-Term
Fixed-Income Securities;
Short-Term
Fixed-Income Investments; and
All
Other
Investments.
The
1940
Act requires periodic valuation of each investment in our portfolio to determine
net asset value. Under the 1940 Act, unrestricted securities with readily
available market quotations are to be valued at the current market value; all
other assets must be valued at "fair value" as determined in good faith by
or
under the direction of the Board of Directors.
Our
Board
of Directors is responsible for (1) determining overall valuation guidelines
and
(2) ensuring the valuation of investments within the prescribed
guidelines.
Our
Valuation Committee, comprised of all of our independent Board members, is
responsible for reviewing and approving the valuation of our assets within
the
guidelines established by the Board of Directors.
Fair
value is generally defined as the amount that an investment could be sold for
in
an orderly disposition over a reasonable time. Generally, to increase
objectivity in valuing our assets, external measures of value, such as public
markets or third-party transactions, are utilized whenever possible. Valuation
is not based on long-term work-out value, nor immediate liquidation value,
nor
incremental value for potential changes that may take place in the
future.
The
values assigned to these investments are based on available information and
do
not necessarily represent amounts that might ultimately be realized, as these
amounts depend on future circumstances and cannot reasonably be determined
until
the individual investments are actually liquidated or become
marketable.
14
Our
valuation policy with respect to the five broad investment categories is as
follows:
Equity-Related
Securities
Equity-related
securities are valued using one or more of the following basic methods of
valuation:
A.
Cost. The
cost
method is based on our original cost. This method is generally used in the
early
stages of a company’s development until significant positive or negative events
occur subsequent to the date of the original investment that dictate a change
to
another valuation method. Some examples of these events are: (1) a major
recapitalization; (2) a major refinancing; (3) a significant third-party
transaction; (4) the development of a meaningful public market for the company’s
common stock; and (5) significant positive or negative changes in a company’s
business.
B.
Analytical Method. The
analytical method is generally used to value an investment position when there
is no established public or private market in the company’s securities or when
the factual information available to us dictates that an investment should
no
longer be valued under either the cost or private market method. This valuation
method is inherently imprecise and ultimately the result of reconciling the
judgments of our Valuation Committee members, based on the data available to
them. The resulting valuation, although stated as a precise number, is
necessarily within a range of values that vary depending upon the significance
attributed to the various factors being considered. Some of the factors
considered may include the financial condition and operating results of the
company, the long-term potential of the business of the company, the values
of
similar securities issued by companies in similar businesses, the proportion
of
the company’s securities we own and the nature of any rights to require the
company to register restricted securities under applicable securities
laws.
C.
Private Market. The
private market method uses actual, executed, historical transactions in a
company’s securities by responsible third parties as a basis for valuation. The
private market method may also use, where applicable, unconditional firm offers
by responsible third parties as a basis for valuation.
D.
Public Market. The
public market method is used when there is an established public market for
the
class of the company’s securities held by us or into which our securities are
convertible. We discount market value for securities that are subject to
significant legal and contractual restrictions. Other securities, for which
market quotations are readily available, are carried at market value as of
the
time of valuation. Market value for securities traded on securities exchanges
or
on the Nasdaq Global Market is the last reported sales price on the day of
valuation. For other securities traded in the over-the-counter market and listed
securities for which no sale was reported on that day, market value is the
mean
of the closing bid price and asked price on that day. This method is the
preferred method of valuation when there is an established public market for
a
company’s securities, as that market provides the most objective basis for
valuation.
Investments
in Intellectual Property or Patents or Research and Development in Technology
or
Product Development
These
investments are carried at fair value using the following basic methods of
valuation:
E.
Cost. The
cost
method is based on our original cost. This method is generally used in the
early
stages of commercializing or developing intellectual property or patents or
research and development in technology or product development until significant
positive or adverse events occur subsequent to the date of the original
investment that dictate a change to another valuation method.
15
F.
Analytical Method. The
analytical method is used to value an investment after analysis of the best
available outside information where the factual information available to us
dictates that an investment should no longer be valued under either the cost
or
private market method. This valuation method is inherently imprecise and
ultimately the result of reconciling the judgments of our Valuation Committee
members. The resulting valuation, although stated as a precise number, is
necessarily within a range of values that vary depending upon the significance
attributed to the various factors being considered. Some of the factors
considered may include the results of research and development, product
development progress, commercial prospects, term of patent and projected
markets.
G.
Private Market. The
private market method uses actual third-party investments in intellectual
property or patents or research and development in technology or product
development as a basis for valuation, using actual executed historical
transactions by responsible third parties. The private market method may also
use, where applicable, unconditional firm offers by responsible third parties
as
a basis for valuation.
As
of
March 31, 2007, we do not have any investments in intellectual property or
patents or research and development in technologies or products.
Long-Term
Fixed-Income Securities
H.
Readily Marketable.
Fixed-income securities for which market quotations are readily available are
carried at market value as of the time of valuation using the most recent bid
quotations when available.
I.
Not Readily Marketable.
Securities for which market quotations are not readily available are carried
at
fair value using one or more of the following basic methods of
valuation:
Fixed-income
securities are valued by independent pricing services that provide market
quotations based primarily on quotations from dealers and brokers, market
transactions, and other sources.
Other
fixed-income securities that are not readily marketable are valued at fair
value
by our Valuation Committee.
Short-Term
Fixed-Income Investments
J.
Short-term fixed-income investments are valued at market value at the time
of
valuation. We value short-term debt with remaining maturity of 60 days or less
at amortized cost.
All
Other Investments
K.
All
other
investments are reported at fair value as determined in good faith by the
Valuation Committee. As of March 31, 2007, we do not have any of these
investments.
16
The
reported values of securities for which market quotations are not readily
available and for other assets reflect the Valuation Committee’s judgment of
fair values as of the valuation date using the outlined basic methods of
valuation. They do not necessarily represent an amount of money that would
be
realized if we had to sell the securities in an immediate liquidation. Thus,
valuations as of any particular date are not necessarily indicative of amounts
that we may ultimately realize as a result of future sales or other dispositions
of investments we hold.
17
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE
1. THE COMPANY
Harris
& Harris Group, Inc. (the
"Company," "us," "our" and "we"), is a venture capital company operating as
a
business development company ("BDC") under the Investment Company Act of 1940
("1940 Act"). We operate as an internally managed company whereby our officers
and employees, under the general supervision of our Board of Directors, conduct
our operations.
We
elected to become a BDC on July 26, 1995, after receiving the necessary
shareholder approvals. From September 30, 1992, until the election of BDC
status, we operated as a closed-end, non-diversified investment company under
the 1940 Act. Upon commencement of operations as an investment company, we
revalued all of our assets and liabilities in accordance with the 1940 Act.
Prior to September 30, 1992, we were registered and filed under the reporting
requirements of the Securities and Exchange Act of 1934 as an operating company
and, while an operating company, operated directly and through
subsidiaries.
Harris
& Harris Enterprises, Inc.SM
("Enterprises"), is a 100 percent wholly owned subsidiary of the Company.
Enterprises is a partner in Harris Partners I, L.P.SM
and is
taxed under Subchapter C of the Code (a “C Corporation”). Harris Partners I,
L.P, is a limited partnership and owns our interest in AlphaSimplex Group,
LLC.
The partners of Harris Partners I, L.P., are Enterprises (sole general partner)
and Harris & Harris Group, Inc. (sole limited partner).
We
filed
for the 1999 tax year to elect treatment as a regulated investment company
("RIC") under Subchapter M of the Internal Revenue Code of 1986 (the "Code")
and
qualified for the same treatment for the years 2000 through 2005 pursuant to
Section 851(e) of the Code. On March 29, 2007, we filed for RIC certification
under Section 851(e) of the Code for 2006, although we qualified as a RIC for
2006 without such certification. However, there can be no assurance that we
will
qualify as a RIC for 2007 or subsequent years. In addition, under certain
circumstances, even if we qualified for Subchapter M treatment for a given
year,
we might take action in a subsequent year to ensure that we would be taxed
in
that subsequent year as a C Corporation, rather than as a RIC. As a RIC, we
must, among other things, distribute at least 90 percent of our investment
company taxable income and may either distribute or retain our realized net
capital gains on investments.
NOTE
2. INTERIM FINANCIAL STATEMENTS
Our
interim financial statements have been prepared in accordance with the
instructions to Form 10-Q and Article 10 of Regulation S-X and in conformity
with generally accepted accounting principles applicable to interim financial
information. Accordingly, they do not include all information and disclosures
necessary for a presentation of our financial position, results of operations
and cash flows in conformity with generally accepted accounting principles
in
the United States of America. In the opinion of management, these financial
statements reflect all adjustments, consisting only of normal recurring
accruals, necessary for a fair presentation of our financial position, results
of operations and cash flows for such periods. The results of operations for
any
interim period are not necessarily indicative of the results for the full year.
These financial statements should be read in conjunction with the financial
statements and notes thereto contained in our Annual
Report on Form 10-K for the fiscal year ended December 31, 2006.
18
NOTE
3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The
following is a summary of significant accounting policies followed in the
preparation of the consolidated financial statements:
Principles
of Consolidation.
The
consolidated financial statements have been prepared in accordance with
accounting principles generally accepted in the United States of America for
investment companies and include the accounts of the Company and its wholly
owned subsidiaries. All significant inter-company accounts and transactions
have
been eliminated in consolidation.
Use
of
Estimates.
The
preparation of the consolidated financial statements in conformity with
accounting principles generally accepted in the United States of America
requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and contingent assets and liabilities as
of
March 31, 2007 and December 31, 2006, and the reported amounts of revenues
and
expenses for the three months ended March 31, 2007 and 2006. The most
significant estimates relate to the fair valuations of certain of our
investments. Actual results could differ from these estimates.
Cash
and Cash Equivalents.
Cash and
cash equivalents include money market instruments with maturities of less than
three months.
Portfolio
Investment Valuations.
Investments are stated at "value" as defined in the 1940 Act and in the
applicable regulations of the SEC. Value, as defined in Section 2(a)(41) of
the
1940 Act, is (i) the market price for those securities for which a market
quotation is readily available and (ii) the fair value as determined in good
faith by, or under the direction of, the Board of Directors for all other
assets. (See "Valuation Procedures" in the "Footnote to Consolidated Schedule
of
Investments.") At March 31, 2007, our financial statements include private
venture capital investments valued at $54,694,963, the fair values of which
were
determined in good faith by, or under the direction, of the Board of Directors.
Upon sale of investments, the values that are ultimately realized may be
different from what is presently estimated. The difference could be
material.
Foreign
Currency Translation.
The
accounting records of the Company are maintained in U.S. dollars. All assets
and
liabilities denominated in foreign currencies are translated into U.S. dollars
based on the rate of exchange of such currencies against U.S. dollars on the
date of valuation. At March 31, 2007, included in the unrealized loss on
investments was $15,947 resulting from foreign currency
translation.
Securities
Transactions.
Securities transactions are accounted for on the date the securities are
purchased or sold (trade date); dividend income is recorded on the ex-dividend
date; and interest income is accrued as earned. The Company ceases accruing
interest when securities are determined to be non-income producing and writes
off any previously accrued interest. Realized gains and losses on investment
transactions are determined by specific identification for financial reporting
and tax reporting.
Stock-Based
Compensation.
The
Company has a stock-based employee compensation plan. The Company accounts
for
the plan in accordance with the provisions of SFAS No. 123(R), "Share-Based
Payment." See Note 4 for further discussion.
19
Income
Taxes.
Prior to
our conversion to a RIC in 1999, our taxes were accounted for in accordance
with
Statement of Financial Accounting Standards ("SFAS") No. 109.
We
pay
federal, state and local income taxes on behalf of our wholly owned subsidiary,
Harris & Harris Enterprises, which is a C corporation. (See "Note 7. Income
Taxes.")
In
June
2006, the FASB issued Interpretation 48, “Accounting
for Uncertainty in Income Taxes” (“FIN 48”),
an interpretation of FASB Statement No. 109, “Accounting
for Income Taxes.” FIN 48
clarifies the accounting and reporting for income taxes where interpretation
of
the law is uncertain. FIN 48 prescribes a comprehensive model for the
financial statement recognition, measurement, presentation and disclosure of
income tax uncertainties with respect to positions taken or expected to be
taken
in income tax returns. FIN 48 is effective for fiscal years beginning after
December 15, 2006. The Company adopted this Statement on January 1,
2007, which had no effect on the Company's financial statements. The Company
recognizes interest and penalties in income tax expense. See Note 7 for further
discussion.
Restricted
Funds.
The
Company maintains a rabbi trust for the purposes of accumulating funds to
satisfy the obligations incurred by us for the Supplemental Executive Retirement
Plan ("SERP") under the employment agreement with Charles E. Harris.
Property
and Equipment.
Property
and equipment are included in "Other Assets" and are carried at cost, less
accumulated depreciation of $289,880. Depreciation is provided using the
straight-line method over the estimated useful lives of the premises and
equipment.
Recent
Accounting Pronouncements.
In
February 2007, the FASB issued Statement No. 159, “The
Fair Value Option for Financial Assets and Financial Liabilities”
(“SFAS 159”).
SFAS 159 would allow the Company an irrevocable election to measure certain
financial assets and liabilities at fair value, with unrealized gains and losses
on the elected items recognized in earnings at each reporting period. The fair
value option may only be elected at the time of initial recognition of a
financial asset or financial liability or upon the occurrence of certain
specified events. The election is applied on an instrument by instrument basis,
with a few exceptions, and is applied only to entire instruments and not to
portions of instruments. SFAS 159 also provides expanded disclosure
requirements regarding the effects of electing the fair value option on the
financial statements. SFAS 159 is effective prospectively for fiscal years
beginning after November 15, 2007. The Company is currently evaluating this
Statement. However, as investments are carried at fair value, the Company does
not anticipate that this statement will have a significant impact on the
consolidated financial statements.
NOTE
4. STOCK-BASED COMPENSATION
On
March
23, 2006, the Board of Directors of the Company voted to terminate the Employee
Profit-Sharing Plan and establish the Harris & Harris Group, Inc. 2006
Equity Incentive Plan (the “Stock Plan”), subject to shareholder approval. This
proposal was approved at the May 4, 2006, Annual Meeting of Shareholders. The
Stock Plan provides for the grant of equity-based awards of stock options and
restricted stock (subject to receipt of an exemption order described below)
to
our directors, officers and employees who are selected by our Compensation
Committee for participation in the plan and subject to compliance with the
1940
Act.
20
On
July
11, 2006, the Company filed an application with the SEC regarding certain
provisions of the Stock Plan. In the event that the SEC provides the exemptive
relief requested by the application and we receive any additional stockholder
approval required by the SEC, the Compensation Committee may, in the future,
authorize awards under the Stock Plan to certain former officers of the Company,
non-employee directors of the Company, authorize grants of restricted stock
and
adjust the exercise price of options to reflect taxes paid for deemed dividends.
A
maximum
of 20 percent of our total shares of our common stock issued and outstanding
are
available for awards under the Stock Plan. Under the Stock Plan, no more than
25
percent of the shares of stock reserved for the grant of the awards under the
Stock Plan may be restricted stock awards at any time during the term of the
Stock Plan. If any shares of restricted stock are awarded, such awards will
reduce on a percentage basis the total number of shares of stock for which
options may be awarded. If the Company does not receive exemptive relief from
the SEC to issue restricted stock, all shares granted under the Stock Plan
may
be subject to stock options. No more than 1,000,000 shares of our common stock
may be made subject to awards under the Stock Plan to any individual in any
year.
On
June
26, 2006, the Compensation Committee of the Board of Directors of the Company
approved individual stock option awards for certain officers and employees
of
the Company. Both non-qualified stock options ("NQSOs") and incentive stock
options ("ISOs"), subject to the limitations of Section 422 of the Internal
Revenue Code, were awarded under the Stock Plan. The terms and conditions of
the
stock options granted were determined by the Compensation Committee and set
forth in award agreements between the Company and each award recipient. A total
of 3,958,283 stock options were granted with vesting periods ranging from
December 2006 to June 2014 and with an exercise price of $10.11. Upon exercise,
the shares will be issued from our previously authorized shares. The full Board
of Directors ratified and approved the grants on August 3, 2006, on which date
the Company's common stock price fluctuated between $9.76 and $10.00.
The
Company accounts for the Stock Plan in accordance with the provisions of SFAS
No. 123(R), “Share-Based Payment,” which requires that we determine the fair
value of all share-based payments to employees, including the fair value of
grants of employee stock options, and record these amounts as an expense in
the
Statement of Operations over the vesting period with a corresponding increase
to
our additional paid-in capital. At March 31, 2007, the increase to our operating
expenses was offset by the increase to our additional paid-in capital, resulting
in no net impact to our net asset value. Additionally, the Company does not
record the tax benefits associated with the expensing of stock options because
the Company intends to qualify as a RIC under Subchapter M of the
Code.
The
amount of stock-based compensation expense recognized in the Consolidated
Statements of Operations is based on the fair value of the awards the Company
expects to vest, recognized over the vesting period on a straight-line basis
for
each award, and adjusted for actual forfeitures that occur before vesting.
The
forfeiture rate is estimated at the time of grant and revised, if necessary,
in
subsequent periods if the actual forfeiture rate differs from the estimated
rate.
For
the
three months ended March 31, 2007, the Company recognized $1,690,181 of
compensation expense in the Consolidated Statements of Operations. As of March
31, 2007, there was approximately $8,393,087 of unrecognized compensation cost
related to unvested stock option awards. This cost is expected to be recognized
over a weighted-average period of approximately 1.86 years.
21
For
the
three months ended March 31, 2007, a total of 326,012 shares were exercised
for
total proceeds to the Company of $3,295,978.
For
the
three months ended March 31, 2007, the calculation of the net decrease in net
assets resulting from operations per share excludes the stock options because
such options were anti-dilutive. The options may be dilutive in future periods
in which there is a net increase in net assets resulting from operations in
the
event that there is a significant increase in the average stock price in the
stock market or significant decreases in the amount of unrecognized compensation
cost.
A
summary
of the changes in outstanding stock options is as follows:
Weighted
|
||||||||||||||||
Weighted
|
Weighted
|
Average
|
||||||||||||||
Average
|
Average
|
Remaining
|
Aggregate
|
|||||||||||||
Exercise
|
Grant
Date
|
Contractual
|
Intrinsic
|
|||||||||||||
Shares
|
Price
|
Fair
Value
|
Term
(Yrs)
|
Value
|
||||||||||||
Options
Outstanding at January 1, 2007
|
3,699,611
|
$
|
10.11
|
$
|
4.43
|
|||||||||||
Granted
|
-
|
-
|
-
|
|||||||||||||
Exercised
|
326,012
|
$
|
10.11
|
$
|
1.74
|
$
|
916,094
|
|||||||||
Forfeited
or Expired
|
-
.
|
|||||||||||||||
Options
Outstanding at March 31, 2007
|
3,373,599
|
$
|
10.11
|
$
|
4.68
|
4.76
|
$
|
9,479,813
|
||||||||
Options
Exercisable at March 31, 2007
|
741,017
|
$
|
10.11
|
$
|
3.71
|
3.84
|
$
|
2,082,258
|
||||||||
Options
Exercisable and Expected to be Exercisable
at March 31, 2007
|
3,007,610
|
$
|
10.11
|
$
|
4.63
|
4.71
|
$
|
8,451,384
|
The
aggregate intrinsic value in the table above is calculated as the difference
between the Company's closing stock price of $12.92 on the last trading day
of
the first quarter of 2007 and the exercise price, multiplied by the number
of
in-the-money options. This represents the total pre-tax intrinsic value that
would have been received by the option holders had all option holders fully
vested and exercised their awards on March 31, 2007.
Unless
earlier terminated by our Board of Directors, the Stock Plan will expire on
May
4, 2016. The expiration of the Stock Plan will not by itself adversely affect
the rights of plan participants under awards that are outstanding at the time
the Stock Plan expires. Our Board of Directors may terminate, modify or suspend
the plan at any time, provided that no modification of the plan will be
effective unless and until any required shareholder approval has been obtained.
The Compensation Committee may terminate, modify or amend any outstanding award
under the Stock Plan at any time, provided that in such event, the award holder
may exercise any vested options prior to such termination of the Stock Plan
or
award.
22
NOTE
5. EMPLOYEE PROFIT-SHARING PLAN
Prior
to
the adoption of the Stock Plan, the Company operated the Amended and Restated
Harris & Harris Group, Inc. Employee Profit-Sharing Plan (the "2002 Plan").
Effective May 4, 2006, the 2002 Plan was terminated.
The
2002
Plan (and its predecessor) provided for profit sharing by our officers and
employees equal to 20 percent of our "qualifying income" for that plan
year.
As
soon
as practicable following the year-end, the Compensation Committee determined
whether, and if so how much, qualifying income existed for a plan year.
Approximately, 90 percent of the amount determined by the Compensation
Committee was then paid out to Plan participants pursuant to the distribution
percentages set forth in the 2002 Plan. The remaining payment was paid out
after
we finalized our tax returns for that plan year.
At
March
31, 2007, and December 31, 2006, we accrued $0 and $261,661, respectively,
for
profit sharing. On March 1, 2006, the Company paid $1,897,072 to plan
participants (employees and former employees), which represented approximately
90 percent of the total estimated profit-sharing payment for 2005. The balance
of $261,661 was paid on January 31, 2007, upon finalization of our tax
returns.
As
discussed in Note 4, subject to receiving exemptive relief from the SEC, the
Company may permit certain former officers of the Company to be participants
of
the Stock Plan. Alternatively, the SEC may provide relief which would permit
us
to pay out the remainder, if any, of the former officers' grandfathered
participations under the terminated 2002 Plan.
NOTE
6. DISTRIBUTABLE EARNINGS
As
of
December 31, 2006, and March 31, 2007, there were no distributable earnings.
The
difference between the book basis and tax basis components of distributable
earnings is primarily nondeductible deferred compensation and net operating
losses.
NOTE
7. INCOME TAXES
Provided
that a proper election is made, a corporation taxable under Subchapter C of
the
Code or a C Corporation that elects to qualify as a RIC continues to be taxable
as a C Corporation on any gains realized within 10 years of its qualification
as
a RIC (the "Inclusion Period") from sales of assets that were held by the
corporation on the effective date of the RIC election ("C Corporation Assets"),
to the extent of any gain built into the assets on such date ("Built-In Gain").
If the corporation fails to make a proper election, it is taxable on its
Built-In Gain as of the effective date of its RIC election. We had Built-In
Gains at the time of our qualification as a RIC and made the election to be
taxed on any Built-In Gain realized during the Inclusion Period.
23
We
adopted FIN 48 as of January 1, 2007, the beginning of our fiscal year. As
of
January 1, 2007, we had unrecognized tax benefits of $0 and did not record
any
cumulative effect adjustment to net assets as a result of adopting FIN
48.
For
federal tax purposes, the Company’s 2003 through 2006 tax years remain open for
examination by the tax authorities under the normal three year statute of
limitations. Generally, for state tax purposes, the Company’s 2002 through 2006
tax years remain open for examination by the tax authorities under a four year
statute of limitations.
During
the first quarter of 2007, we paid $9,455 in federal income taxes. At March
31,
2007, we had $74,454 accrued for interest and penalties.
We
pay
federal, state and local taxes on behalf of our wholly owned subsidiary, Harris
& Harris Enterprises, Inc., which is taxed as a C Corporation. For the three
months ended March 31, 2007, and 2006, our income tax expense (benefit) for
Harris & Harris Enterprises, Inc., was $0 and $9,606, respectively.
Continued
qualification as a RIC requires us to satisfy certain investment asset
diversification requirements in future years. Our ability to satisfy those
requirements may not be controllable by us. There can be no assurance that
we
will qualify as a RIC in subsequent years.
NOTE
8. CAPITAL TRANSACTIONS
On
November 29, 2006, we filed a registration statement with the SEC on Form N-2
with respect to 4,000,000 shares of our common stock. On December 11, 2006,
and
on April 23, 2007, we filed amended registration statements with the SEC. After
the effective date, the common stock may be sold at prices and on terms to
be
set forth in one or more supplements to the prospectus from time to
time.
In
September of 2005, we completed the sale of 3,507,500 shares for gross proceeds
of $37,091,813; net proceeds of the offering, after offering costs of $565,246,
were $36,526,567. We intend to use, and have been using, the net proceeds of
the
offering to make new investments in tiny technology as well as follow-on
investments in our existing venture capital investments, and for working
capital.
NOTE
9. SUBSEQUENT EVENTS
On
April
26, 2007, we made a $233,918 follow-on investment in a privately held tiny
technology portfolio company.
On
April
30, 2007, we made a $680,240 follow-on investment in a privately held tiny
technology portfolio company.
On
May 3,
2007, we made an $800,000 new investment in a privately held tiny technology
portfolio company.
24
HARRIS
& HARRIS GROUP, INC.
FINANCIAL
HIGHLIGHTS
(Unaudited)
Three
Months Ended March 31
|
|
||||||
|
|
2007
|
|
2006
|
|||
Per
Share Operating Performance
|
|||||||
Net
asset value per share, beginning of period
|
$
|
5.42
|
$
|
5.68
|
|||
Net
operating loss*
|
(0.13
|
)
|
(0.04
|
)
|
|||
Net
realized income (loss) on investments*
|
0
|
0
|
|||||
Net
increase in unrealized depreciation
|
|||||||
as
a result of sales*
|
0
|
0
|
|||||
Net
increase in unrealized depreciation
|
|||||||
on
investments held*
|
(0.17
|
)
|
(0.04
|
)
|
|||
Total
from investment operations*
|
(.30
|
)
|
(0.08
|
)
|
|||
Net
increase as a result of stock-based compensation
|
0.08
|
0
|
|||||
Net
increase as a result of proceeds from exercise
|
|||||||
of
options
|
0.07
|
0
|
|||||
Total
increase from capital stock transactions
|
0.15
|
0
|
|||||
Net
asset value per share, end of period
|
$
|
5.27
|
$
|
5.60
|
|||
Stock
price per share, end of period
|
$
|
12.92
|
$
|
13.95
|
|||
Total
return based on stock price (1)
|
6.87
|
%
|
0.36
|
%
|
|||
Supplemental
Data:
|
|||||||
Net
assets, end of period
|
$
|
112,526,302
|
$
|
116,333,752
|
|||
Ratio
of expenses to average net assets (1)
|
2.9
|
%
|
1.3
|
%
|
|||
Ratio
of net operating loss to average net assets (1)
|
(2.4
|
)%
|
(0.7
|
%)
|
|||
Cash
dividends paid per share
|
$
|
0
|
$
|
0
|
|||
Deemed
dividend per share
|
$
|
0
|
$
|
0
|
|||
Number
of shares outstanding, end of period
|
21,341,029
|
20,756,345
|
*Based
on
Average Shares Outstanding.
(1)
Not
Annualized
The
accompanying notes are an integral part of this schedule.
25
Item
2. Management's
Discussion and Analysis of Financial Condition and
Results of Operations
The
information contained in this section should be read in conjunction with the
Company's unaudited March 31, 2007 Consolidated Financial Statements and the
Company's audited 2006 Consolidated Financial Statements and notes
thereto.
Background
and Overview
We
incorporated under the laws of the state of New York in August 1981. In 1983,
we
completed an initial public offering and invested $406,936 in Otisville BioTech,
Inc., which also completed an initial public offering later that year. In 1984,
Charles E. Harris purchased a controlling interest in us which also made him
the
control person of Otisville. We then divested our other assets and became a
financial services company, with the investment in Otisville as the initial
focus of our business activity.
In
1992,
we registered as an investment company under the 1940 Act, commencing operations
as a closed-end, non-diversified investment company. In 1995, we elected to
become a business development company subject to the provisions of Sections
55
through 65 of the 1940 Act.
Throughout
our corporate history, we have made early stage venture capital investments
in a
variety of industries. We define venture capital investments as investments
in
start-up firms and small businesses with exceptional growth potential. We have
invested a substantial portion of our assets in venture capital investments
of
private, development stage or start-up companies. These private businesses
tend
to be thinly capitalized, unproven, small companies that lack management depth,
have little or no history of operations and are developing unproven
technologies. At March 31, 2007, $54,694,963, or 48.61 percent, of our net
assets at fair value consisted of private venture capital investments, net
of
unrealized depreciation of $12,284,021. At December 31, 2006, $53,667,831,
or
47.1 percent, of our net assets at fair value consisted of private venture
capital investments, net of unrealized depreciation of $8,450,969.
Since
our
investment in Otisville in 1983 through March 31, 2007, we have made a total
of
74 venture capital investments, including four private placement investments
in
securities of publicly traded companies. We have sold 44 of these 74
investments, realizing total proceeds of $143,614,382 on our invested capital
of
$51,229,202. As measured from first dollar in to last dollar out, the average
and median holding periods for these 44 investments were 3.63 years and 3.19
years, respectively. As measured by the 149 separate rounds of investment within
these 44 investments, the average and median holding periods for the 149
separate rounds of investment were 2.84 years and 2.44 years,
respectively.
In
1994,
we made our first tiny technology investment. From August 2001 through March
31,
2007, all 32 of our initial investments have been in tiny technology. From
August 2001 through March 31, 2007, we have invested a total (before any
subsequent write-ups, write-downs or dispositions) of $70,897,446 in tiny
technology.
26

The
following is a summary of our initial and follow-on investments in tiny
technology from 2001 to the present. We consider a "round led" to be a round
where we were the new investor or the leader of a set of new investors in an
investee company. Typically, but not always, the lead investor negotiates the
price and terms of a deal with the investee company.
2001
|
2002
|
2003
|
2004
|
2005
|
2006
|
2007
|
||||||||||||||||
Total
Incremental Investments
|
$
|
489,999
|
$
|
6,240,118
|
$
|
3,812,600
|
$
|
14,837,846
|
$
|
16,251,339
|
$
|
24,408,187
|
$
|
4,857,357
|
||||||||
No.
of New Investments
|
1
|
7
|
5
|
8
|
4
|
6
|
1
|
|||||||||||||||
No.
of Follow-On Investment Rounds
|
0
|
1
|
5
|
21
|
13
|
14
|
6
|
|||||||||||||||
No.
of Rounds Led
|
0
|
1
|
0
|
2
|
0
|
7
|
1
|
|||||||||||||||
Average
Dollar Amount - Initial
|
$
|
489,999
|
$
|
784,303
|
$
|
437,156
|
$
|
911,625
|
$
|
1,575,000
|
$
|
2,383,424
|
$
|
1,147,826
|
||||||||
Average
Dollar Amount - Follow-On
|
N/A
|
$
|
750,000
|
$
|
325,364
|
$
|
359,278
|
$
|
765,488
|
$
|
721,974
|
$
|
618,255
|
27
We
currently have 28 tiny technology companies in our portfolio. At March 31,
2007,
from first dollar in, the average and median holding periods for these 28
venture capital investments were 2.92 years and 2.37 years,
respectively.
We
value
our private venture capital investments each quarter as determined in good
faith
by our Valuation Committee, a committee of all of our independent directors,
within guidelines established by our Board of Directors in accordance with
the
1940 Act. (See "Footnote to Consolidated Schedule of Investments" contained
in
"Consolidated Financial Statements.")
In
the
years 2001, 2002, 2003, 2004, 2005 and 2006, the Company recorded the following
gross write-downs in privately held securities as a percentage of net assets
at
the beginning of the year:
|
2001
|
2002
|
2003
|
2004
|
2005
|
2006
|
YTD
2007
|
|||||||||||||||
Net
Asset Value, Beginning of Year
|
$
|
31,833,475
|
$
|
24,334,770
|
$
|
27,256,046
|
$
|
40,682,738
|
$
|
74,744,799
|
$
|
117,987,742
|
$
|
113,930,303
|
||||||||
Gross
Write-Downs During Year
|
$
|
(2,532,730
|
)
|
$
|
(5,400,005
|
)
|
$
|
(1,256,102
|
)
|
$
|
(5,711,229
|
)
|
$
|
(3,450,236
|
)
|
$
|
(4,211,323
|
)
|
$
|
(4,043,077
|
)
|
|
Gross
Write-Downs as a Percentage of Net Asset Value
|
-7.96
|
%
|
-22.19
|
%
|
-4.61
|
%
|
-14.04
|
%
|
-4.62
|
%
|
-3.57
|
%
|
-3.55
|
%
|
The
following is a history of the changes in our per share NAV, by
quarter:
31-Dec-00
|
|
31-Mar-01
|
|
30-June-01
|
|
30-Sep-01
|
|
31-Dec-01
|
||||||||
NAV
per Share
|
$
|
3.51
|
$
|
3.09
|
$
|
3.29
|
$
|
2.92
|
$
|
2.75
|
||||||
$
Change
|
(0.42
|
)
|
0.20
|
(0.37
|
)
|
(0.17
|
)
|
|||||||||
%
Change
|
-11.97
|
%
|
6.47
|
%
|
-11.25
|
%
|
-5.82
|
%
|
31-Mar-02
|
|
|
30-June-02
|
|
|
30-Sep-02(1)
|
|
|
31-Dec-02
|
|||||||
NAV
per Share
|
$
|
2.63
|
$
|
2.68
|
$
|
2.61
|
$
|
2.37
|
||||||||
$
Change
|
(0.12
|
)
|
0.05
|
(0.07
|
)
|
(0.24
|
)
|
|||||||||
%
Change
|
-4.36
|
%
|
1.90
|
%
|
-2.61
|
%
|
-9.20
|
%
|
31-Mar-03
|
|
|
30-June-03
|
|
|
30-Sep-03
|
|
|
31-Dec-03(1)
|
|
||||||
NAV
per Share
|
$
|
2.26
|
$
|
2.22
|
$
|
2.11
|
$
|
2.95
|
||||||||
$
Change
|
(0.11
|
)
|
(0.04
|
)
|
(0.11
|
)
|
0.84
|
|||||||||
%
Change
|
-4.64
|
%
|
-1.77
|
%
|
-4.95
|
%
|
39.81
|
%
|
31-Mar-04
|
30-June-04
|
|
|
30-Sep-04(1)
|
|
|
31-Dec-04
|
|||||||||
NAV
per Share
|
$
|
3.01
|
$
|
2.85
|
$
|
4.44
|
$
|
4.33
|
||||||||
$
Change
|
0.06
|
(0.16
|
)
|
1.59
|
(0.11
|
)
|
||||||||||
%
Change
|
2.03
|
%
|
-5.32
|
%
|
55.79
|
%
|
-2.48
|
%
|
31-Mar-05
|
30-June-05
|
|
|
30-Sep-05(1)
|
|
|
31-Dec-05
|
|||||||||
NAV
per Share
|
$
|
4.20
|
$
|
4.61
|
$
|
5.94
|
$
|
5.68
|
||||||||
$
Change
|
(0.13
|
)
|
0.41
|
1.33
|
(0.26
|
)
|
||||||||||
%
Change
|
-3.00
|
%
|
9.76
|
%
|
28.85
|
%
|
-4.38
|
%
|
28
|
31-Mar-06
|
30-June-06
|
30-Sep-06
|
31-Dec-06
|
|||||||||
NAV
per Share
|
$5.60
|
$5.54
|
$5.54
|
$5.42
|
|||||||||
$
Change
|
(0.08)
|
(0.06)
|
0.00
|
(0.12)
|
|||||||||
%
Change
|
-1.41%
|
-1.07%
|
0.00%
|
-2.17%
|
|||||||||
31-Mar-07
|
|||||||||||||
NAV
per Share
|
5.27
|
||||||||||||
$
Change
|
(0.15
|
) | |||||||||||
%
Change
|
-2.77
|
(1) The
Company completed issuances for new shares of our common stock on September
14,
2005, July 7, 2004, December 24, 2003 and July 8, 2002.
We
have
discretion in the investment of our capital. However, we invest primarily in
illiquid equity securities of private companies. Generally, these investments
take the form of preferred stock, are subject to restrictions on resale and
have
no established trading market. Our principal objective is to achieve long-term
capital appreciation. Therefore, a significant portion of our investment
portfolio provides little or no income in the form of dividends or interest.
We
earn interest income from fixed-income securities, including U.S. government
and
agency securities. The amount of interest income we earn varies with the average
balance of our fixed-income portfolio and the average yield on this portfolio.
Interest income is secondary to capital gains and losses in our results of
operations.
We
present the financial results of our operations utilizing accounting principles
generally accepted in the United States for investment companies. On this basis,
the principal measure of our financial performance during any period is the
net
increase/(decrease) in our net assets resulting from our operating activities,
which is the sum of the following three elements:
Net
Operating Income / (Loss)
- the
difference between our income from interest, dividends, and fees and our
operating expenses.
Net
Realized Income / (Loss) on Investments
- the
difference between the net proceeds of sales of portfolio securities and their
stated cost, plus income from interests in limited liability
companies.
Net
Increase / (Decrease) in Unrealized Appreciation or Depreciation on
Investments
- the
net unrealized change in the value of our investment portfolio.
Owing
to
the structure and objectives of our business, we generally expect to experience
net operating losses and seek to generate increases in our net assets from
operations through the long term appreciation of our venture capital
investments. We have relied, and continue to rely, on proceeds from sales of
investments and on sales of additional shares, rather than on investment income,
to defray a significant portion of our operating expenses. Because such sales
are unpredictable, we attempt to maintain adequate working capital to provide
for fiscal periods when there are no such sales.
29
Results
of Operations
Three
months ended March 31, 2007, as compared to the three months ended March 31,
2006
In
the
three months ended March 31, 2007, and March 31, 2006, we had net decreases
in
net assets resulting from operations of $6,390,160 and $1,653,990, respectively.
Investment
Income and Expenses:
We
had
net operating losses of $2,667,118 and $767,743 for the three months ended
March
31, 2007, and March 31, 2006, respectively. The variation in these results
is
primarily owing to the changes in investment income and operating expenses.
During the three months ended March 31, 2007, and 2006, total investment income
was $652,498 and $804,862, respectively. During the three months ended March
31,
2007, and 2006, total operating expenses were $3,319,616 and $1,572,605,
respectively.
During
the three months ended March 31, 2007, as compared with the same period in
2006,
investment income decreased owing to a decrease in our average holdings of
U.S.
government and agency securities. During the three months ended March 31, 2007,
our average holdings of such securities were $60,084,828, as compared with
$76,957,955 during the three months ended March 31, 2006.
The
increase in operating expenses for the three months ended March 31, 2007, as
compared to the three months ended March 31, 2006, was primarily owing to
increases in salaries, benefits and stock-based compensation expense, and
directors' fees and expenses partially offset by a decrease in professional
fees. Salaries, benefits and stock-based compensation expense increased by
$1,748,405, or 222.34 percent, through March 31, 2007, as compared to March
31,
2006, primarily as a result of non-cash expense of $1,690,181 associated with
the Stock Plan. While the non-cash stock-based compensation expense for the
Stock Plan increased our operating expenses by $1,690,181, this increase was
offset by a corresponding increase to our additional paid-in capital, resulting
in no net impact to our net asset value. The non-cash stock-based compensation
expense and corresponding increase to our additional paid-in capital may
increase in future quarters. Directors' fees and expenses increased by $55,294,
or 64.4 percent, primarily as a result of additional meetings held in the period
ended March 31, 2007, as well as an increase in the monthly retainers paid
to
Committee Chairs and the Lead Independent Director, as compared with the period
ended March 31, 2006. Professional fees decreased by $107,692, or 37.15 percent,
for the three months ended March 31, 2007, as compared with the same period
in
2006, primarily as a result of a reduction of some legal and accounting
fees.
Realized
Income and Losses from Investments:
During
the three months ended March 31, 2007, we realized net losses on investments
of
$674, as compared with realized net gains on investments of $11,953 during
the
three months ended March 31, 2006.
During
the three months ended March 31, 2007, we realized net losses of $674,
consisting primarily of income from our investment in AlphaSimplex Group, LLC,
offset by losses in Exponential Business Development Company.
During
the three months ended March 31, 2006, we realized net gains of $11,953,
consisting primarily of proceeds received from the liquidation of Optiva, Inc.,
offset by losses realized on our investment in AlphaSimplex Group,
LLC.
30
Net
Unrealized Appreciation and Depreciation of Portfolio
Securities:
During
the three months ended March 31, 2007, net unrealized depreciation on total
investments increased by $3,637,463, or 40.4 percent, from net unrealized
depreciation of $9,007,420 at December 31, 2006, to net unrealized depreciation
of $12,644,883 at March 31, 2007. Net unrealized depreciation on total
investments increased by $888,594, or 19.4 percent, during the three months
ended March 31, 2006, from $4,588,550 at December 31, 2005, to $5,477,145 at
March 31, 2006.
During
the three months ended March 31, 2007, net unrealized depreciation on our
venture capital investments increased by $3,833,052, from $8,450,969 to
$12,284,021, owing primarily to decreases in the valuations of our investments
in Chlorogen, Inc., of $1,370,699, Evolved Nanomaterial Sciences, Inc., of
$1,228,281, Nanomix, Inc., of $459,772, NanoOpto Corporation of $892,409 and
Questech Corporation of $91,916, and an increase in the valuation of our
investment in Polatis, Inc., of $190,680. We also had an increase owing to
foreign currency translation of $18,156 on our investment in D-Wave Systems,
Inc. Unrealized depreciation on our U.S. government and agency securities
portfolio decreased from $556,451 at December 31, 2006, to $360,862 at March
31,
2007.
During
the three months ended March 31, 2006, net unrealized depreciation on our
venture capital investments increased by $191,545, from $4,519,009 to
$4,710,554, owing primarily to a decrease in the valuation of our investment
in
Zia Laser, Inc. Unrealized depreciation on our U.S. government and agency
securities portfolio increased from $69,541 at December 31, 2005, to $766,591
at
March 31, 2006.
Financial
Condition
March
31, 2007
At
March
31, 2007, our total assets and net assets were $116,508,703 and $112,526,302,
respectively. At December 31, 2006, they were $118,328,590 and $113,930,303,
respectively.
At
March
31, 2007, net asset value per share ("NAV") was $5.27, as compared with $5.42
at
December 31, 2006. At March 31, 2007, our shares outstanding increased to
21,341,029, as compared with 21,015,017 at December 31, 2006.
Significant
developments in the three months ended March 31, 2007, included
an increase in the value of our venture capital investments of $1,027,132 and
a
decrease in the value of our investment in U.S. government and agency
obligations of $940,233. The increase in the value of our venture capital
investments, from $53,667,831 at December 31, 2006, to $54,694,963 at March
31,
2007, resulted primarily from one new and six follow-on investments, partially
offset by a net decrease of $3,834,241 in the net value of our previous venture
capital investments. The decrease in the value of our U.S. government and agency
obligations, from $58,656,147 at December 31, 2006, to $57,715,914 at March
31,
2007, is primarily owing to the use of funds for investments totaling
$4,857,357, profit sharing payments of $261,661 and net operating expenses
offset by proceeds received from stock option exercises. During the three months
ended March 31, 2007, the Company issued 326,012 shares of stock and received
proceeds of $3,295,978 as a result of option exercises.
31
The
following table is a summary of additions to our portfolio of venture capital
investments during the three months ended March 31, 2007:
New
Investment
|
Amount
|
|||
Adesto
Technologies Corporation
|
$
|
1,147,826
|
||
Follow-on
Investment
|
||||
BridgeLux,
Inc.
|
$
|
350,877
|
||
Cambrios
Technologies Corporation
|
$
|
1,300,000
|
||
Kereos,
Inc.
|
$
|
540,000
|
||
NanoOpto
Corporation
|
$
|
268,654
|
||
Nextreme
Thermal Solutions, Inc.
|
$
|
750,000
|
||
Solazyme,
Inc.
|
$
|
500,000
|
||
Total
|
$
|
4,857,357
|
The
following tables summarize the fair values of our portfolios of venture capital
investments and U.S. government and agency obligations, as compared with their
cost, at March 31, 2007, and December 31, 2006:
March
31, 2007
|
December
31, 2006
|
||||||
Venture
capital investments,
|
|||||||
at
cost
|
$
|
66,978,984
|
$
|
62,118,800
|
|||
Net
unrealized depreciation (1)
|
12,284,021
|
8,450,969
|
|||||
Venture
capital investments,
|
|||||||
at
fair value
|
$
|
54,694,963
|
$
|
53,667,831
|
March
31, 2007
|
December
31, 2006
|
||||||
U.S.
government and agency
|
|||||||
obligations,
at cost
|
$
|
58,076,776
|
$
|
59,212,598
|
|||
Net
unrealized depreciation(1)
|
360,862
|
556,451
|
|||||
U.S.
government and agency
|
|||||||
obligations,
at fair value
|
$
|
57,715,914
|
$
|
58,656,147
|
1)
At
March
31, 2007, and December 31, 2006, the net accumulated unrealized depreciation
on
investments was $12,644,883 and $9,007,420, respectively.
32
The
following table summarizes the fair value composition of our venture capital
investment portfolio at March 31, 2007, and December 31, 2006.
March
31, 2007
|
December
31, 2006
|
||||||
Category
|
|||||||
Tiny
Technology
|
99.9
|
%
|
99.9
|
%
|
|||
Other
Venture Capital Investments
|
0.1
|
%
|
0.1
|
%
|
|||
Total
Venture Capital Investments
|
100.0
|
%
|
100.0
|
%
|
Liquidity
Our
primary sources of liquidity are cash, receivables and freely marketable
securities, net of short-term indebtedness. Our secondary sources of liquidity
are restricted securities of companies that are publicly traded.
At
March
31, 2007, and December 31, 2006, our total net primary liquidity was $58,829,464
and $61,323,306, respectively, and our secondary liquidity was $0 and $0,
respectively.
The
decrease in our primary liquidity from December 31, 2006, to March 31, 2007,
is
primarily owing to the use of funds for investments and payment of net operating
expenses.
Capital
Resources
In
September 2005, we completed the sale of 3,507,500 common shares, for total
gross proceeds of $37,091,813; net proceeds, after offering costs of $565,246,
were $36,526,567. We intend to use, and have been using, the net proceeds of
this offering to make new investments in tiny technology, as well as for
follow-on investments in our existing venture capital investments and for
working capital. Through March 31, 2007, we have used $25,048,657 of the net
proceeds from this offering for these purposes.
Critical
Accounting Policies
The
Company's significant accounting policies are described in Note 3 to the
Consolidated Financial Statements and in the Footnote to the Consolidated
Schedule of Investments. Critical accounting policies are those that are both
important to the presentation of our financial condition and results of
operations and those that require management’s most difficult, complex or
subjective judgments. The Company considers the following accounting policies
and related estimates to be critical:
Stock-Based
Compensation
Determining
the appropriate fair-value model and calculating the fair value of share-based
awards at the date of grant requires judgment. We use the Black-Scholes option
pricing model to estimate the fair value of employee stock options, consistent
with the provisions of SFAS No. 123(R). Management uses the Black-Scholes
option pricing model because of the lack of historical option data which is
required for use in other, more complex models. Other models may yield fair
values that are significantly different from those calculated by the
Black-Scholes option pricing model.
33
Option
pricing models, including the Black-Scholes model, require the use of subjective
input assumptions, including expected volatility, expected life, expected
dividend rate, and expected risk-free rate of return. In the Black-Scholes
model, variations in the expected volatility or expected term assumptions have
a
significant impact on fair value. As the volatility or expected term assumptions
increase, the fair value of the stock option increases. In the Black-Scholes
model, the expected dividend rate and expected risk-free rate of return are
not
as significant to the calculation of fair value. A higher assumed dividend
rate
yields a lower fair value, whereas higher assumed interest rates yield higher
fair values for stock options.
We
use
the simplified calculation of expected life described in the SEC’s Staff
Accounting Bulletin 107, because of the lack of historical information about
option exercise patterns. Future exercise behavior could be materially different
than that which is assumed by the model.
Expected
volatility is based on the historical fluctuations in the Company's stock.
The
Company's stock has historically been volatile, which increases the fair
value.
SFAS
No. 123(R) requires us to develop an estimate of the number of share-based
awards that will be forfeited owing to employee turnover. Quarterly changes
in
the estimated forfeiture rate can have a significant effect on reported
share-based compensation, as the effect of adjusting the rate for all expense
amortization after June 30, 2006, is recognized in the period the forfeiture
estimate is changed. If the actual forfeiture rate proves to be higher than
the
estimated forfeiture rate, then an adjustment will be made to increase the
estimated forfeiture rate, which would result in a decrease to the expense
recognized in the financial statements. If the actual forfeiture rate proves
to
be lower than the estimated forfeiture rate, then an adjustment will be made
to
decrease the estimated forfeiture rate, which would result in an increase to
the
expense recognized in the financial statements. Such adjustments would affect
our operating expenses and additional paid-in capital, but would have no effect
on our net asset value.
Valuation
of Portfolio Investments
As
a
business development company, we invest in illiquid securities including debt
and equity securities of private companies. These investments are generally
subject to restrictions on resale and generally have no established trading
market. We value substantially all of our equity investments at fair value
as
determined in good faith by our Valuation Committee on a quarterly basis. The
Valuation Committee, comprised of all of our non-interested Board members,
reviews and approves the valuation of our investments within the valuation
procedures established by the Board of Directors. Fair value is generally
defined as the amount that an investment could be sold for in an orderly
disposition over a reasonable time. Generally, to increase objectivity in
valuing our assets, external measures of value, such as public markets or third
party transactions, are utilized whenever possible. Valuation is not based
on
long-term work-out value, nor immediate liquidation value, nor incremental
value
for potential changes that may take place in the future. Upon sale of
investments, the values that are ultimately realized may be different from
what
is presently estimated. This difference could be material.
34
Pension
and Post-Retirement Benefit Plan Assumptions
The
Company provides a Retiree Medical Benefit Plan for employees who meet certain
eligibility requirements. Several statistical and other factors that attempt
to
anticipate future events are used in calculating the expense and liability
values related to our post-retirement benefit plans. These factors include
assumptions we make about the discount rate, the rate of increase in healthcare
costs, and mortality, among others.
The
discount rate reflects the current rate at which the post-retirement benefit
liabilities could be effectively settled considering the timing of expected
payments for plan participants. In estimating this rate, we consider rates
of
return on high quality fixed-income investments included in published bond
indexes. We consider the Moody’s Aa Corporate Bond Index and the Citigroup
Pension Liability Index in the determination of the appropriate discount rate
assumptions. The weighted average rate we utilized to measure our post
retirement benefit obligation as of December 31, 2006, and to calculate our
2007 expense was 5.75 percent, which is an increase from the 5.5 percent rate
used in determining the 2006 expense.
Recent
Developments — Portfolio Companies
On
April
26, 2007, we made a $233,918 follow-on investment in a privately held tiny
technology portfolio company.
On
April
30, 2007, we made a $680,240 follow-on investment in a privately held tiny
technology portfolio company.
On
May 3,
2007, we made an $800,000 new investment in a privately held tiny technology
portfolio company.
Forward-Looking
Statements
The
information contained herein contains certain forward-looking statements. These
statements include the plans and objectives of management for future operations
and financial objectives, portfolio growth and availability of funds. These
forward-looking statements are subject to the inherent uncertainties in
predicting future results and conditions. Certain factors that could cause
actual results and conditions to differ materially from those projected in
these
forward-looking statements are set forth herein. Other factors that could cause
actual results to differ materially include the uncertainties of economic,
competitive and market conditions, and future business decisions, all of which
are difficult or impossible to predict accurately and many of which are beyond
our control. Although we believe that the assumptions underlying the
forward-looking statements included herein are reasonable, any of the
assumptions could be inaccurate and, therefore, there can be no assurance that
the forward-looking statements included or incorporated by reference herein
will
prove to be accurate. Therefore, the inclusion of such information should not
be
regarded as a representation by us or any other person that our plans will
be
achieved.
35
Item
3. Quantitative
and Qualitative Disclosures About Market Risk
Our
business activities contain elements of risk. We consider the principal types
of
market risk to be valuation risk and the risk associated with fluctuations
in
interest rates. Although we are risk-seeking rather than risk-averse in our
investments, we consider the management of risk to be essential to our business.
Value,
as
defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those
securities for which market quotations are readily available and (ii) fair
value
as determined in good faith by, or under the direction of, the Board of
Directors for all other assets. (See the "Valuation Procedures" in the "Footnote
to Consolidated Schedule of Investments" contained in "Item 1. Consolidated
Financial Statements.")
Neither
our investments nor an investment in us is intended to constitute a balanced
investment program.
We
have
invested a substantial portion of our assets in private development stage or
start-up companies. These private businesses tend to be based on new technology
and to be thinly capitalized, unproven, small companies that lack management
depth and have not attained profitability or have no history of operations.
Because of the speculative nature and the lack of a public market for these
investments, there is significantly greater risk of loss than is the case with
traditional investment securities. We expect that some of our venture capital
investments will be a complete loss or will be unprofitable and that some will
appear to be likely to become successful but never realize their potential.
Even
when our private equity investments complete initial public offerings (IPOs),
we
are normally subject to lock-up agreements for a period of time, and thereafter,
the market for the unseasoned publicly traded securities may be relatively
illiquid.
Because
there is typically no public market for our interests in the small privately
held companies in which we invest, the valuation of the equity interests in
that
portion of our portfolio is determined in good faith by our Valuation Committee,
comprised of the independent members of our Board of Directors, in accordance
with our Valuation Procedures. In the absence of a readily ascertainable market
value, the determined value of our portfolio of equity interests may differ
significantly from the values that would be placed on the portfolio if a ready
market for the equity interests existed. Any changes in valuation are recorded
in our consolidated statements of operations as "Net increase (decrease) in
unrealized appreciation on investments." Changes in valuation of any of our
investments in privately held companies from one period to another may be
volatile.
We
also
invest in short-term money market instruments, and both short and long-term
U.S.
government and agency securities. To the extent that we invest in short and
long-term U.S. government and agency securities, changes in interest rates
may
result in changes in the value of these obligations which would result in an
increase or decrease of our net asset value. The level of interest rate risk
exposure at any given point in time depends on the market environment, the
expectations of future price and market movements, and the quantity and duration
of both the short and long-term U.S. government and agency securities held
by
the Company, and it will vary from period to period. If the average interest
rate on U. S. government and agency securities at March 31, 2007, were to
increase by 25, 75 and 150 basis points, the weighted average value of these
securities held by us at March 31, 2007, would decrease by approximately
$249,601, $748,802 and $1,497,604, respectively, and our net asset value would
decrease correspondingly.
Most
of
our investments are denominated in U.S. dollars. We currently have one
investment denominated in Canadian dollars. We are exposed to foreign currency
risk related to potential changes in foreign currency exchange rates. The
potential loss in fair value on this investment resulting from a 10 percent
adverse change in quoted foreign currency exchange rates is $173,460 at March
31, 2007.
36
In
addition, in the future, we may from time to time opt to borrow money to make
investments. Our net investment income will be dependent upon the difference
between the rate at which we borrow funds and the rate at which we invest such
funds. As a result, there can be no assurance that a significant change in
market interest rates will not have a material adverse effect on our net
investment income in the event we choose to borrow funds for investing
purposes.
Item
4. Controls and Procedures
(a)
Disclosure
Controls and Procedures. As
of the
end of the period covered by this report, the Company’s management, under the
supervision and with the participation of our chief executive officer and chief
financial officer, conducted an evaluation of the effectiveness of the design
and operation of our disclosure controls and procedures (as required by Rules
13a-15 of the Securities Exchange Act of 1934 (the "1934 Act")). Disclosure
controls and procedures means controls and other procedures of an issuer that
are designed to ensure that information required to be disclosed by the issuer
in the reports that it files or submits under the 1934 Act is recorded,
processed, summarized and reported, within time periods specified in the SEC's
rules and forms, and that such information is accumulated and communicated
to
the issuer's management, as appropriate, to allow timely decisions regarding
required disclosures. As of March 31, 2007, based upon this evaluation of our
disclosure controls and procedures, our chief executive officer and chief
financial officer concluded that our disclosure controls and procedures were
effective.
(b)
Changes
in Internal Control Over Financial Reporting. There
have not been any changes in the Company's internal control over financial
reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the
Exchange Act) during the first quarter of 2007 to which this report relates
that
have materially affected, or are reasonably likely to materially affect, the
Company’s internal control over financial reporting.
37
PART
II. OTHER INFORMATION
Item
1A. Risk
Factors
Investing
in our common stock involves significant risks relating to our business and
investment objective. You should carefully consider the risks and uncertainties
described in our Annual Report on Form 10-K for the year ended December 31,
2006, before you purchase any of our common stock. The risks described in our
Annual Report on Form 10-K are not the only risks facing our Company. Unknown
additional risks and uncertainties, or ones that we currently consider
immaterial, may also impair our business. If any of these risks or uncertainties
materialize, our business, financial condition or results of operations could
be
materially adversely affected. In this event, the trading price of our common
stock could decline, and you could lose all or part of your
investment.
Our
portfolio companies may generate revenues from the sale of non-tiny
technology-enabled products.
We
consider a company to be a tiny technology company if a product or products,
or
intellectual property covering a product or products, that we consider to be
at
the microscale or smaller is material to its business plan. The core business
of
some of these companies may not be tiny technology-enabled products, and
therefore their success or failure may not be dependent upon the tiny technology
aspects of their business. In addition to developing products that we consider
tiny technology, some of these companies may also develop products that we
do
not consider enabled by tiny technology. Some of these companies will generate
revenues from the sale of non-tiny technology-enabled products. Additionally,
it
is possible that a portfolio company may decide to change its business focus
after our initial investment and decide to develop and commercialize non-tiny
technology-enabled products.
Item
6. Exhibits
31.01* |
Certification
of CEO pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.
|
31.02* |
Certification
of CFO pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.
|
32.01* |
Certification
of CEO and CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to
Section 906 of the Sarbanes-Oxley Act of
2002.
|
*filed
herewith
38
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
caused this report to be signed on its behalf by the undersigned, thereunto
duly
authorized on behalf of the Registrant and as its chief accounting
officer.
Harris
& Harris Group, Inc.
|
||
|
|
|
By: | /s/ Douglas W. Jamison | |
Douglas W. Jamison, President |
||
and
Chief Financial Officer
|
By: |
/s/ Patricia
N. Egan
|
|
Patricia N. Egan |
||
Chief Accounting Officer | ||
and
Vice President
|
||
Date:
May 10, 2007
|
39
EXHIBIT
INDEX
Exhibit
No.
|
Description
|
|
31.01
|
Certification
of CEO pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.
|
|
31.02
|
Certification
of CFO pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.
|
|
32.01
|
Certification
of CEO and CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of
2002.
|
40